About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
A comprehensive discussion of the causes, epidemiology, diagnosis, symptoms, and pharmacotherapy for this movement disorder is presented, with an emphasis on the efficacy and adverse effects of pharmaceutical treatments.
Marvin M. Goldenberg, PhD, RPh, MS
Health Care and Law
Although the intricacies of health care regulation may seem inefficient and unwieldy, our system of local, state, and national checks and balances actually makes a certain amount of sense. Dr. Field discusses the logic behind the complexities of the present regulatory system.
Robert I. Field, JD, MPH, PhD
Obama and McCain Positions Similar — with One Major Difference
The outlook for Medicare Part D and universal health insurance coverage may depend, in part, on who is elected President and how Congress decides to act.
The Multiple Sclerosis Trend Report reveals the need for many improvements in treating this expensive and complex disease, such as containing costs of biotech drugs, easing the process of obtaining patient reimbursements and physician payments, developing a role for specialty pharmacy, and eliminating barriers to patient–pharmacy communication.
Mari Edlin and Peter Sonnenreich, MA
David Nash, MD, MBA, talks about a new school of health policy to open next year at Thomas Jefferson University.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how easy it is to misprogram pumps used for patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the need for Congress to fund a program to evaluate the cost effectiveness of drugs and medical devices.
From Altace to Zyprexa, P&T presents the latest studies and information about FDA approvals, new indications, product recalls, and industry updates.
Dr. Erowele reviews alvimopan, a mu-opioid receptor antagonist (Entereg), for postoperative ileus.
Goldina Ikezuagu Erowele, PharmD